Citadel Advisors
ARTV

Citadel Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Citadel Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.91M Buy
609,376
+593,506
+3,740% +$5.41M ﹤0.01% 4441
2026
Q1 		$102K Buy
+15,870
New +$78.5K ﹤0.01% 12005
2025
Q4 		– Sell
-798,397
Closed -$2.29M – 14393
2025
Q3 		$2.29M Buy
798,397
+644,658
+419% +$1.72M ﹤0.01% 5804
2025
Q2 		$232K Buy
153,739
+8,650
+6% +$18.2K ﹤0.01% 10376
2025
Q1 		$435K Buy
145,089
+41,454
+40% +$224K ﹤0.01% 8782
2024
Q4 		$992K Hold
103,635
– – ﹤0.01% 7040
2024
Q3 		$1.52M Buy
+103,635
New +$1.2M ﹤0.01% 6025

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Citadel Advisors's ARTV Position: Q2 2026 in Review

Citadel Advisors increased its Artiva Biotherapeutics (ARTV) stake by 3,740% in Q2 2026, buying an estimated $5.41M and bringing the position to 609,376 shares worth $5.91M. The position accounts for ﹤0.01% of the portfolio, ranked #4441.

Citadel Advisors first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Citadel Advisors held 609,376 shares of Artiva Biotherapeutics worth $5.91M as of Q2 2026.
  • Citadel Advisors bought 593,506 Artiva Biotherapeutics shares in Q2 2026, an estimated $5.41M.
  • Artiva Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4441 holding.
  • Citadel Advisors first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.